Orchestra BioMed (OBIO) Competitors

$3.72 -0.39 (-9.49%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$3.82 +0.09 (+2.55%)

As of 05/15/2026 06:39 PM Eastern

OBIO vs. DRTS, INMD, BVS, SSII, and SGP

Should you buy Orchestra BioMed stock or one of its competitors? MarketBeat compares Orchestra BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orchestra BioMed include Alpha Tau Medical (DRTS), InMode (INMD), Bioventus (BVS), SS Innovations International (SSII), and Spyglass Pharma (SGP). These companies are all part of the "medical equipment" industry.

How does Orchestra BioMed compare to Alpha Tau Medical?

Alpha Tau Medical (NASDAQ:DRTS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Alpha Tau Medical has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Alpha Tau Medical's return on equity of -57.29% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Tau Medical	N/A	-57.29%	-42.39%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Alpha Tau Medical presently has a consensus price target of $10.75, suggesting a potential upside of 3.76%. Orchestra BioMed has a consensus price target of $14.50, suggesting a potential upside of 289.78%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Orchestra BioMed is more favorable than Alpha Tau Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Tau Medical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alpha Tau Medical has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

In the previous week, Alpha Tau Medical had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 11 mentions for Alpha Tau Medical and 10 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.37 beat Alpha Tau Medical's score of 0.36 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Tau Medical	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.7% of Alpha Tau Medical shares are held by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are held by institutional investors. 39.5% of Alpha Tau Medical shares are held by company insiders. Comparatively, 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Alpha Tau Medical has higher earnings, but lower revenue than Orchestra BioMed. Alpha Tau Medical is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Tau Medical	N/A	N/A	-$42.63M	-$0.53	N/A
Orchestra BioMed	$33.48M	6.65	-$52.70M	-$0.97	N/A

Summary

Alpha Tau Medical beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to InMode?

InMode (NASDAQ:INMD) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

InMode has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMode	$374.64M	2.35	$93.83M	$1.36	10.22
Orchestra BioMed	$33.48M	6.65	-$52.70M	-$0.97	N/A

InMode has a net margin of 23.27% compared to Orchestra BioMed's net margin of -166.96%. InMode's return on equity of 13.47% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMode	23.27%	13.47%	11.95%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

InMode has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

InMode currently has a consensus price target of $16.00, indicating a potential upside of 15.11%. Orchestra BioMed has a consensus price target of $14.50, indicating a potential upside of 289.78%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Orchestra BioMed had 6 more articles in the media than InMode. MarketBeat recorded 10 mentions for Orchestra BioMed and 4 mentions for InMode. InMode's average media sentiment score of 0.73 beat Orchestra BioMed's score of 0.37 indicating that InMode is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMode	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

68.0% of InMode shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

InMode beats Orchestra BioMed on 10 of the 16 factors compared between the two stocks.

How does Orchestra BioMed compare to Bioventus?

Bioventus (NASDAQ:BVS) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Bioventus has higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.56	$22.73M	$0.41	25.80
Orchestra BioMed	$33.48M	6.65	-$52.70M	-$0.97	N/A

Bioventus has a net margin of 4.94% compared to Orchestra BioMed's net margin of -166.96%. Bioventus' return on equity of 29.97% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

Bioventus has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Orchestra BioMed has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

Bioventus currently has a consensus price target of $14.00, indicating a potential upside of 32.33%. Orchestra BioMed has a consensus price target of $14.50, indicating a potential upside of 289.78%. Given Orchestra BioMed's higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Orchestra BioMed had 8 more articles in the media than Bioventus. MarketBeat recorded 10 mentions for Orchestra BioMed and 2 mentions for Bioventus. Bioventus' average media sentiment score of 0.44 beat Orchestra BioMed's score of 0.37 indicating that Bioventus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 53.2% of Orchestra BioMed shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Comparatively, 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Bioventus beats Orchestra BioMed on 13 of the 17 factors compared between the two stocks.

How does Orchestra BioMed compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

SS Innovations International has higher revenue and earnings than Orchestra BioMed. SS Innovations International is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	18.18	-$12.13M	-$0.05	N/A
Orchestra BioMed	$33.48M	6.65	-$52.70M	-$0.97	N/A

53.2% of Orchestra BioMed shares are owned by institutional investors. 7.5% of Orchestra BioMed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SS Innovations International has a net margin of -20.69% compared to Orchestra BioMed's net margin of -166.96%. SS Innovations International's return on equity of -23.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Orchestra BioMed	-166.96%	-157.46%	-60.18%

In the previous week, Orchestra BioMed had 5 more articles in the media than SS Innovations International. MarketBeat recorded 10 mentions for Orchestra BioMed and 5 mentions for SS Innovations International. SS Innovations International's average media sentiment score of 0.49 beat Orchestra BioMed's score of 0.37 indicating that SS Innovations International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Orchestra BioMed has a consensus price target of $14.50, indicating a potential upside of 289.78%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

SS Innovations International beats Orchestra BioMed on 8 of the 15 factors compared between the two stocks.

How does Orchestra BioMed compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Spyglass Pharma has a net margin of 0.00% compared to Orchestra BioMed's net margin of -166.96%. Spyglass Pharma's return on equity of 0.00% beat Orchestra BioMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Orchestra BioMed	-166.96%	-157.46%	-60.18%

In the previous week, Orchestra BioMed had 7 more articles in the media than Spyglass Pharma. MarketBeat recorded 10 mentions for Orchestra BioMed and 3 mentions for Spyglass Pharma. Orchestra BioMed's average media sentiment score of 0.37 beat Spyglass Pharma's score of -0.38 indicating that Orchestra BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Orchestra BioMed	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

53.2% of Orchestra BioMed shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Spyglass Pharma currently has a consensus price target of $45.00, indicating a potential upside of 93.88%. Orchestra BioMed has a consensus price target of $14.50, indicating a potential upside of 289.78%. Given Orchestra BioMed's higher possible upside, analysts clearly believe Orchestra BioMed is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Orchestra BioMed	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Spyglass Pharma has higher earnings, but lower revenue than Orchestra BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Orchestra BioMed	$33.48M	6.65	-$52.70M	-$0.97	N/A

Summary

Orchestra BioMed beats Spyglass Pharma on 6 of the 11 factors compared between the two stocks.

Get Orchestra BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBIO vs. The Competition

Export

Metric	Orchestra BioMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$246.11M	$3.38B	$6.43B	$12.48B
Dividend Yield	N/A	2.32%	2.80%	5.25%
P/E Ratio	-3.84	18.34	20.38	25.24
Price / Sales	6.65	293.90	566.19	82.25
Price / Cash	N/A	124.05	43.04	56.04
Price / Book	5.39	6.63	9.87	6.90
Net Income	-$52.70M	$24.40M	$3.57B	$334.66M
7 Day Performance	-7.92%	4.15%	0.31%	0.13%
1 Month Performance	-16.78%	-2.65%	-1.27%	1.11%
1 Year Performance	28.28%	62.87%	33.54%	30.62%

Orchestra BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBIO Orchestra BioMed	3.6531 of 5 stars	$3.72 -9.5%	$14.50 +289.8%	+28.7%	$246.11M	$33.48M	N/A	4	News Coverage Earnings Report Analyst Forecast
DRTS Alpha Tau Medical	1.8066 of 5 stars	$9.88 -4.4%	$10.75 +8.8%	+250.0%	$910.02M	N/A	N/A	80	Upcoming Earnings Analyst Forecast
INMD InMode	1.9711 of 5 stars	$13.83 +0.4%	$16.00 +15.7%	-5.5%	$872.45M	$374.64M	10.17	480
BVS Bioventus	4.141 of 5 stars	$10.14 -0.5%	$14.00 +38.1%	N/A	$847.35M	$568.09M	24.73	1,200
SSII SS Innovations International	1.3587 of 5 stars	$4.11 +0.7%	N/A	-61.2%	$816.54M	$42.49M	N/A	4	Earnings Report Analyst Upgrade Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OBIO) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orchestra BioMed (OBIO) Competitors

OBIO vs. DRTS, INMD, BVS, SSII, and SGP

How does Orchestra BioMed compare to Alpha Tau Medical?

Summary

How does Orchestra BioMed compare to InMode?

Summary

How does Orchestra BioMed compare to Bioventus?

Summary

How does Orchestra BioMed compare to SS Innovations International?

Summary

How does Orchestra BioMed compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orchestra BioMed (OBIO) Competitors

OBIO vs. DRTS, INMD, BVS, SSII, and SGP

How does Orchestra BioMed compare to Alpha Tau Medical?

Is DRTS or OBIO more profitable?

Do analysts rate DRTS or OBIO?

Which has more risk & volatility, DRTS or OBIO?

Does the media refer more to DRTS or OBIO?

Do institutionals & insiders hold more shares of DRTS or OBIO?

Which has stronger valuation & earnings, DRTS or OBIO?

Summary

How does Orchestra BioMed compare to InMode?

Which has better earnings & valuation, INMD or OBIO?

Is INMD or OBIO more profitable?

Which has more volatility and risk, INMD or OBIO?

Do analysts prefer INMD or OBIO?

Does the media prefer INMD or OBIO?

Do institutionals and insiders believe in INMD or OBIO?

Summary

How does Orchestra BioMed compare to Bioventus?

Which has stronger earnings and valuation, BVS or OBIO?

Is BVS or OBIO more profitable?

Which has more risk and volatility, BVS or OBIO?

Do analysts prefer BVS or OBIO?

Does the media favor BVS or OBIO?

Do insiders & institutionals believe in BVS or OBIO?

Summary

How does Orchestra BioMed compare to SS Innovations International?

Which has stronger earnings and valuation, SSII or OBIO?

Do insiders & institutionals believe in SSII or OBIO?

Is SSII or OBIO more profitable?

Does the media refer more to SSII or OBIO?

Do analysts prefer SSII or OBIO?

Summary

How does Orchestra BioMed compare to Spyglass Pharma?

Is SGP or OBIO more profitable?

Does the media favor SGP or OBIO?

Do institutionals & insiders believe in SGP or OBIO?

Do analysts prefer SGP or OBIO?

Which has higher valuation & earnings, SGP or OBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBIO vs. The Competition

Orchestra BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools